Takeharu Yamanaka
#95,167
Most Influential Person Now
Japanese statistician and mayor of Yokohama
Takeharu Yamanaka's AcademicInfluence.com Rankings
Takeharu Yamanakamathematics Degrees
Mathematics
#7923
World Rank
#10768
Historical Rank
Statistics
#1041
World Rank
#1142
Historical Rank
Download Badge
Mathematics
Why Is Takeharu Yamanaka Influential?
(Suggest an Edit or Addition)According to Wikipedia, Takeharu Yamanaka is a Japanese politician and current mayor of Yokohama, the capital of Kanagawa Prefecture. He defeated incumbent mayor Fumiko Hayashi in the 2021 Yokohama mayoral election. His independent campaign was supported by the Constitutional Democratic Party, Social Democratic Party, and the Communist Party of Japan. Yamanaka's campaign focused on the opposition for a planned integrated resort development and casino for the city which was to be built on Yamashita Pier, criticism against the government's response to the COVID-19 pandemic, and additional sister city relationship with San Francisco, California.
Takeharu Yamanaka's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. (2010) (1480)
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer (2019) (846)
- Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. (2014) (645)
- Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography. (2016) (566)
- Duration of Adjuvant Chemotherapy for Stage III Colon Cancer (2018) (557)
- The Baseline Ratio of Neutrophils to Lymphocytes Is Associated with Patient Prognosis in Advanced Gastric Cancer (2008) (417)
- Sarcopenia as a predictor of prognosis in patients following hepatectomy for hepatocellular carcinoma (2013) (392)
- Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. (2017) (295)
- Preoperative Neutrophil-to-Lymphocyte Ratio Is a Predictor of Survival After Hepatectomy for Hepatocellular Carcinoma: A Retrospective Analysis (2013) (272)
- Intramuscular Transplantation of G‐CSF‐Mobilized CD34+ Cells in Patients With Critical Limb Ischemia: A Phase I/IIa, Multicenter, Single‐Blinded, Dose‐Escalation Clinical Trial (2009) (237)
- Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer. (2018) (174)
- Advances in esophageal cancer surgery in Japan: an analysis of 1000 consecutive patients treated at a single institute. (2008) (169)
- Risk factors associated with surgical site infection in upper and lower gastrointestinal surgery (2008) (166)
- Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer. (2006) (160)
- Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies (2020) (147)
- Prognostic index for acute- and lymphoma-type adult T-cell leukemia/lymphoma. (2011) (134)
- Clinical significance of the 21‐gene signature (Oncotype DX) in hormone receptor‐positive early stage primary breast cancer in the Japanese population (2010) (111)
- Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials. (2020) (101)
- Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients (2015) (95)
- Evaluation of cartilage invasion by laryngeal and hypopharyngeal squamous cell carcinoma with dual-energy CT. (2012) (89)
- Solid tumors versus mixed tumors with a ground-glass opacity component in patients with clinical stage IA lung adenocarcinoma: prognostic comparison using high-resolution computed tomography findings. (2013) (85)
- The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV (2019) (83)
- Predictive value of chemotherapy-induced neutropenia for the efficacy of oral fluoropyrimidine S-1 in advanced gastric carcinoma (2007) (79)
- Impact of Serum Hepatocyte Growth Factor on Treatment Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non–Small Cell Lung Adenocarcinoma (2010) (79)
- A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer (2015) (77)
- Economic evaluation of the 21-gene signature (Oncotype DX®) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03) (2011) (74)
- A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L. (2015) (71)
- Long-term outcomes after hematopoietic SCT for adult T-cell leukemia/lymphoma: results of prospective trials (2011) (70)
- Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study (2015) (70)
- Evaluation of Pancreatic Endocrine and Exocrine Function in Patients With Autoimmune Pancreatitis (2007) (69)
- Clinical significance of salvage esophagectomy for remnant or recurrent cancer following definitive chemoradiotherapy (2011) (69)
- Palmitate-induced lipotoxicity is crucial for the pathogenesis of nonalcoholic fatty liver disease in cooperation with gut-derived endotoxin (2018) (68)
- Oral and Parenteral Versus Parenteral Antibiotic Prophylaxis in Elective Laparoscopic Colorectal Surgery (JMTO PREV 07–01): A Phase 3, Multicenter, Open-label, Randomized Trial (2016) (67)
- Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial. (2015) (67)
- Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer (2019) (67)
- Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation–positive non-squamous non–small-cell lung cancer (NSCLC): Survival follow-up results of JO25567. (2018) (66)
- A phase ΙI study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study) (2014) (65)
- Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study. (2016) (63)
- 12-Gene Recurrence Score Assay Stratifies the Recurrence Risk in Stage II/III Colon Cancer With Surgery Alone: The SUNRISE Study. (2016) (62)
- Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study). (2020) (61)
- A Randomized Study of Distal Filter Protection Versus Conventional Treatment During Percutaneous Coronary Intervention in Patients With Attenuated Plaque Identified by Intravascular Ultrasound. (2018) (59)
- Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, multicenter, pilot study (2017) (57)
- Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild‐type KRAS colorectal cancer‐WJOG 6210G (2016) (54)
- Neutrophil-to-lymphocyte ratio predicts prostatic carcinoma in men undergoing needle biopsy (2015) (54)
- Allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning for adult T cell leukemia/lymphoma: impact of antithymocyte globulin on clinical outcome. (2008) (54)
- Prophylactic cranial irradiation (PCI) has a detrimental effect on the overall survival (OS) of patients (pts) with extensive disease small cell lung cancer (ED-SCLC): Results of a Japanese randomized phase III trial. (2014) (54)
- Portal Vein Thrombosis After Hepatectomy (2014) (53)
- Evaluating the 21-gene assay Recurrence Score® as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer (2013) (52)
- Trimodality strategy for treating malignant pleural mesothelioma: results of a feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation (Japan Mesothelioma Interest Group 0601 Trial) (2015) (50)
- Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study (2017) (50)
- Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02) (2018) (50)
- Neutrophil-to-lymphocyte ratio is a prognostic marker in bladder cancer patients after radical cystectomy (2016) (48)
- Postoperative complications are predictive of poor prognosis in hepatocellular carcinoma. (2015) (48)
- A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer (2019) (46)
- Coexistence of the loss of heterozygosity at the PTEN locus and HER2 overexpression enhances the Akt activity thus leading to a negative progesterone receptor expression in breast carcinoma (2007) (45)
- Simultaneous identification of 36 mutations in KRAS codons 61and 146, BRAF, NRAS, and PIK3CA in a single reaction by multiplex assay kit (2013) (44)
- Gene Interaction Network Suggests Dioxin Induces a Significant Linkage between Aryl Hydrocarbon Receptor and Retinoic Acid Receptor Beta (2004) (44)
- CIRCULATE‐Japan: Circulating tumor DNA–guided adaptive platform trials to refine adjuvant therapy for colorectal cancer (2021) (44)
- Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer. (2020) (42)
- Prognostic and Predictive Value of HER2 Amplification in Patients With Metastatic Colorectal Cancer (2018) (41)
- Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer (2021) (40)
- Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study. (2020) (39)
- S-1 Plus Cisplatin with Concurrent Radiotherapy for Locally Advanced Non-small Cell Lung Cancer: A Multi-Institutional Phase II Trial (West Japan Thoracic Oncology Group 3706) (2011) (39)
- Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing (2015) (39)
- Changes in estrogen receptors α and β expression in the brain of mice exposed prenatally to bisphenol A (2007) (37)
- A Phase 2 Study of Atezolizumab for Pretreated NSCLC With Idiopathic Interstitial Pneumonitis (2020) (37)
- A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First‐line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study (2018) (37)
- Comparison of MR Imaging and Dual-Energy CT for the Evaluation of Cartilage Invasion by Laryngeal and Hypopharyngeal Squamous Cell Carcinoma (2018) (37)
- Prognostic Impact of Body Mass Index in Patients with Squamous Cell Carcinoma of the Esophagus (2013) (36)
- Prospective pooled analysis of four randomized trials investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months {m}) for patients (pts) with high-risk stage II colorectal cancer (CC). (2019) (34)
- Placebo-Controlled, Double-Blinded Phase III Study Comparing Dexamethasone on Day 1 With Dexamethasone on Days 1 to 3 With Combined Neurokinin-1 Receptor Antagonist and Palonosetron in High-Emetogenic Chemotherapy. (2018) (34)
- A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum: WJOG7112G (T-ACT). (2018) (34)
- Bevacizumab beyond disease progression after first‐line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non–small cell lung cancer (West Japan Oncology Group 5910L): An open‐label, randomized, phase 2 trial (2016) (34)
- Survival Outcomes of Two Phase 2 Studies of Adjuvant Chemotherapy with S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Patients with Gastric Cancer After D2 Gastrectomy (2018) (34)
- REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients (2019) (32)
- A randomized phase II trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP. (2018) (32)
- Phase II Study of Docetaxel and S-1 (DS) as Neoadjuvant Chemotherapy for Clinical Stage III Resectable Gastric Cancer (2014) (32)
- Lubiprostone improves intestinal permeability in humans, a novel therapy for the leaky gut: A prospective randomized pilot study in healthy volunteers (2017) (31)
- Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial) (2019) (31)
- Wisteria floribunda agglutinin‐positive Mac‐2‐binding protein and type 4 collagen 7S: useful markers for the diagnosis of significant fibrosis in patients with non‐alcoholic fatty liver disease (2018) (31)
- Treatment of patients with adult T cell leukemia/lymphoma with cord blood transplantation: a Japanese nationwide retrospective survey. (2014) (30)
- Impact of Energy Devices During Liver Parenchymal Transection: A Multicenter Randomized Controlled Trial (2015) (30)
- Randomized clinical trial of skin closure by subcuticular suture or skin stapling after elective colorectal cancer surgery (2015) (30)
- Preoperative High Maximum Standardized Uptake Value in Association with Glucose Transporter 1 Predicts Poor Prognosis in Pancreatic Cancer (2017) (30)
- The postoperative recurrence and the occurrence of second primary carcinomas in patients with early gastric carcinoma (2008) (29)
- Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial (2021) (28)
- Utility of the quasi‐monomorphic variation range in unresectable metastatic colorectal cancer patients (2018) (27)
- Expression changes in arrestin β 1 and genetic variation in catechol-O-methyltransferase are biomarkers for the response to morphine treatment in cancer patients. (2012) (27)
- Phase II study of crizotinib in east Asian patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC). (2016) (27)
- Gene interaction network analysis suggests differences between high and low doses of acetaminophen. (2006) (26)
- The TAO-Gen Algorithm for Identifying Gene Interaction Networks with Application to SOS Repair in E. coli (2004) (25)
- Prospective study evaluating the plasma concentrations of twenty-six cytokines and response to morphine treatment in cancer patients. (2011) (24)
- Pooled analysis of S-1 trials in non-small cell lung cancer according to histological type. (2010) (24)
- Combined Analysis of Concordance between Liquid and Tumor Tissue Biopsies for RAS Mutations in Colorectal Cancer with a Single Metastasis Site: The METABEAM Study (2021) (24)
- A randomised phase II trial of S-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for unresectable, locally advanced non-small cell lung cancer: WJOG5008L (2018) (24)
- BMI, body composition, and the energy requirement for body weight gain in patients with anorexia nervosa. (2009) (23)
- Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes study (Y-AIDA study) (2019) (23)
- Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation–positive nonsquamous non-small cell lung cancer (NSCLC): An open-label randomized trial. (2014) (23)
- Impact of intra-abdominal absorbable sutures on surgical site infection in gastrointestinal and hepato-biliary-pancreatic surgery: results of a multicenter, randomized, prospective, phase II clinical trial (2017) (23)
- Multicenter phase I/II study of nivolumab combined with paclitaxel plus ramucirumab as the second-line treatment in patients with advanced gastric cancer. (2019) (23)
- Distributions in CEA doubling time differ in patients with recurrent colorectal carcinomas. (2004) (21)
- Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer. (2021) (20)
- Safety evaluation of oral fluoropyrimidine S-1 for short- and long-term delivery in advanced gastric cancer: analysis of 3,758 patients (2007) (20)
- Clinical Validation of Newly Developed Multiplex Kit Using Luminex xMAP Technology for Detecting Simultaneous RAS and BRAF Mutations in Colorectal Cancer: Results of the RASKET-B Study1 (2018) (20)
- Phase II study of zoledronic acid combined with docetaxel for non-small-cell lung cancer: West Japan Oncology Group (2014) (20)
- Safety data from the phase III Japanese ACHIEVE trial: part of an international, prospective, planned pooled analysis of six phase III trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer (2018) (20)
- Changes in estrogen receptors alpha and beta expression in the brain of mice exposed prenatally to bisphenol A. (2007) (19)
- Preoperative concurrent chemoradiotherapy of S-1/cisplatin for stage III non-small cell lung cancer. (2013) (19)
- Randomized Phase II Study of Adjuvant Chemotherapy with Long-term S-1 versus Cisplatin+S-1 in Completely Resected Stage II–IIIA Non–Small Cell Lung Cancer (2015) (19)
- A phase II open-label single-arm study of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer (NSCLC): Luret study. (2016) (19)
- Molecular detection and clinicopathological characteristics of advanced/recurrent biliary tract carcinomas harboring the FGFR2 rearrangements: a prospective observational study (PRELUDE Study) (2020) (19)
- Differences in surgical site infection between laparoscopic colon and rectal surgeries: sub-analysis of a multicenter randomized controlled trial (Japan-Multinational Trial Organization PREV 07-01) (2016) (19)
- Methodological aspects of current problems in target-based anticancer drug development (2006) (19)
- Rapid detection of neutralizing antibodies to SARS-CoV-2 variants in post-vaccination sera (2021) (18)
- Clinical outcome of Japanese metastatic colorectal cancer patients harbouring the KRAS p.G13D mutation treated with cetuximab + irinotecan. (2012) (18)
- Oxaliplatin-Based Adjuvant Chemotherapy Duration (3 vs. 6 Months) for High-Risk Stage II Colon Cancer: The Randomized Phase 3 ACHIEVE-2 Trial. (2020) (18)
- A Phase II Trial of Everolimus in Patients with Advanced Pancreatic Neuroendocrine Carcinoma Refractory or Intolerant to Platinum-Containing Chemotherapy (NECTOR Trial) (2020) (18)
- Drain Placement After Uncomplicated Hepatic Resection Increases Severe Postoperative Complication Rate: A Japanese Multi-institutional Randomized Controlled Trial (ND-trial). (2020) (18)
- Identification of serum prognostic biomarkers of severe COVID-19 using a quantitative proteomic approach (2021) (18)
- Randomized Phase III Study of Cisplatin With Pemetrexed and Cisplatin With Vinorelbine for Completely Resected Nonsquamous Non–Small‐Cell Lung Cancer: The JIPANG Study Protocol (2018) (17)
- A feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation for malignant pleural mesothelioma. (2008) (17)
- Phase III randomised trial comparing 6 vs. 12-month of capecitabine as adjuvant chemotherapy for patients with stage III colon cancer: final results of the JFMC37-0801 study (2019) (17)
- Analysis of risk factors for severe adverse effects of oral 5-fluorouracil S-1 in patients with advanced gastric cancer (2007) (17)
- Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: COMPASS (WJOG5610L). (2019) (17)
- Palonosetron (PALO) versus granisetron (GRA) in the triplet regimen with dexamethasone (DEX) and aprepitant (APR) for preventing chemotherapy-induced nausea and vomiting (CINV) in patients (pts) receiving highly emetogenic chemotherapy (HEC) with cisplatin (CDDP): A randomized, double-blind, phase I (2013) (16)
- Multicenter Phase I/II Study of Nivolumab Combined with Paclitaxel Plus Ramucirumab as Second-line Treatment in Patients with Advanced Gastric Cancer (2020) (15)
- Sustained Neutralizing Antibodies 6 Months Following Infection in 376 Japanese COVID-19 Survivors (2021) (15)
- The best platinum regimens for chemo-naive incurable non-small cell lung cancer: network meta-analysis (2017) (15)
- Randomized phase II study of TJ-54 (Yokukansan) for postoperative delirium in gastrointestinal and lung malignancy patients (2017) (15)
- Risk factors associated with chemotherapy-induced nausea and vomiting in the triplet antiemetic regimen including palonosetron or granisetron for cisplatin-based chemotherapy: analysis of a randomized, double-blind controlled trial (2018) (15)
- REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer (2021) (15)
- REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients. (2019) (14)
- Frequent microsatellite instability in non-Hodgkin lymphomas irresponsive to chemotherapy. (2008) (14)
- Development of an Automated Chemiluminescence Assay System for Quantitative Measurement of Multiple Anti-SARS-CoV-2 Antibodies (2020) (14)
- Time-dependent change in relapse sites of renal cell carcinoma after curative surgery (2018) (14)
- CYP2D6 Genotype-Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase II Study. (2019) (14)
- Renal toxicity caused by brand-name versus generic cisplatin: a comparative analysis. (2013) (14)
- Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial. (2020) (14)
- Sample Size Calculations Based on Ranking and Selection in Microarray Experiments (2008) (13)
- REVERCE: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan—Biomarker analysis. (2018) (13)
- Randomized phase III study of pemetrexed/cisplatin (Pem/Cis) versus vinorelbine /cisplatin (Vnr/Cis) for completely resected stage II-IIIA non-squamous non-small-cell lung cancer (Ns-NSCLC): The JIPANG study. (2019) (13)
- Impact of clinical response to neoadjuvant endocrine therapy on patient outcomes: a follow-up study of JFMC34-0601 multicentre prospective neoadjuvant endocrine trial (2018) (13)
- A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancer (2016) (13)
- OA08.02 Phase II Study of Erlotinib in Advanced Non-Small Cell Lung Cancer Patients with Leptomeningeal Metastasis (LOGIK1101) (2017) (13)
- Randomized trial to compare LSA2L2‐type maintenance therapy to daily 6‐mercaptopurine and weekly methotrexate with vincristine and dexamethasone pulse for children with acute lymphoblastic leukemia (2010) (12)
- Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database. (2021) (12)
- Phase I/II trial of gemcitabine plus oral TS-1 in elderly patients with advanced non-small cell lung cancer: Thoracic oncology research group study 0502. (2010) (12)
- A Phase II Study of Tri-weekly Low-dose Nab-paclitaxel Chemotherapy for Patients with Advanced Gastric Cancer (2018) (12)
- Impact of treatment with bevacizumab beyond disease progression: a randomized phase II study of docetaxel with or without bevacizumab after platinum-based chemotherapy plus bevacizumab in patients with advanced nonsquamous non–small cell lung cancer (WJOG 5910L) (2012) (12)
- The longitudinal BMI pattern and body composition of patients with anorexia nervosa who require urgent hospitalization: A case control study (2011) (12)
- Prognostic factors in previously treated non-small cell lung cancer patients with and without a positive response to the subsequent treatment with gefitinib. (2009) (12)
- Effect of intra-abdominal absorbable sutures on surgical site infection (2011) (12)
- Surgical Outcomes of Reduced-Port Laparoscopic Gastrectomy Versus Conventional Laparoscopic Gastrectomy for Gastric Cancer: A Propensity-Matched Retrospective Cohort Study (2018) (12)
- Current knowledge of and attitudes toward human papillomavirus‐related disease prevention among Japanese: A large‐scale questionnaire study (2019) (12)
- Morphologic approach to hepatocellular carcinoma development in man: de novo or the so-called 'dysplastic nodule-carcinoma' sequence? (2002) (12)
- Corticosteroids for hospitalized patients with mild to critically-ill COVID-19: a multicenter, retrospective, propensity score-matched study (2020) (11)
- Efficacy and safety of enoxaparin for preventing venous thromboembolic events after laparoscopic colorectal cancer surgery: a randomized-controlled trial (YCOG 1404) (2019) (11)
- Effect of tofogliflozin and pioglitazone on hepatic steatosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A randomized, open-label pilot study (ToPiND study) (2019) (11)
- Efficacy and safety of PERIOdontal treatment versus usual care for Nonalcoholic liver disease: protocol of the PERION multicenter, two-arm, open-label, randomized trial (2020) (11)
- Adjuvant gefitinib versus cisplatin/vinorelbine in Japanese patients with completely resected, EGFR-mutated, stage II-III non-small cell lung cancer (IMPACT, WJOG6410L): A randomized phase 3 trial. (2021) (11)
- Delayed Gastric Emptying After Stapled Versus Hand-Sewn Anastomosis of Duodenojejunostomy in Pylorus-Preserving Pancreaticoduodenectomy: a Randomized Controlled trial (2016) (11)
- Effectiveness of acyclovir prophylaxis against varicella zoster virus disease after allogeneic hematopoietic cell transplantation: A systematic review and meta‐analysis (2019) (11)
- A prospective multicenter observational study of surgical palliation examining postoperative quality of life in patients treated for malignant gastric outlet obstruction caused by incurable advanced gastric cancer. (2017) (11)
- Amrubicin as second-line and beyond treatment for platinum-refractory advanced thymic carcinoma. (2013) (11)
- LBA24Efficacy of 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer (CC): Results from phase III ACHIEVE trial as part of the International Duration Evaluation of Adjuvant therapy (IDEA) Collaboration (2017) (10)
- A multicenter prospective study of carboplatin and paclitaxel for advanced thymic carcinoma: West Japan Oncology Group 4207L. (2013) (10)
- A multicenter, open label, randomized phase II study of osimertinib plus ramucirumab versus osimertinib alone as initial chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer: TORG1833. (2019) (10)
- Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab (2019) (10)
- Rationale for and Design of the PARADIGM Study: Randomized Phase III Study of mFOLFOX6 Plus Bevacizumab or Panitumumab in Chemotherapy‐naïve Patients With RAS (KRAS/NRAS) Wild‐type, Metastatic Colorectal Cancer (2017) (10)
- Reassessment of the utility of frozen sections in endometrial cancer surgery using tumor diameter as an additional factor. (2011) (10)
- Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non–small cell lung cancer (WJOG 5910L): An open-label, randomized, phase II trial. (2015) (10)
- Short-Term Outcomes from a Randomized Screening Phase II Non-inferiority Trial Comparing Omentectomy and Omentum Preservation for Locally Advanced Gastric Cancer: the TOP-G Trial (2021) (10)
- Exclusive KRAS mutation in microsatellite-unstable human colorectal carcinomas with sequence alterations in the DNA mismatch repair gene, MLH1. (2008) (10)
- Clustering of significant genes in prognostic studies with microarrays: Application to a clinical study for multiple myeloma (2008) (10)
- Metabolomic-/Lipidomic-based Analysis of Plasma to Diagnose Hepatocellular Ballooning in Patients with Nonalcoholic Fatty Liver Disease: A Multicenter Study. (2020) (9)
- Randomized phase II study of chemoradiotherapy with cisplatin + S-1 versus cisplatin + pemetrexed for locally advanced non-squamous non-small cell lung cancer: SPECTRA study. (2020) (9)
- Tumor mutation burden as a biomarker for lung cancer patients treated with pemetrexed and cisplatin (the JIPANG‐TR) (2020) (9)
- Beneficial effect of early infusion of landiolol, a very short-acting beta-1 adrenergic receptor blocker, on reperfusion status in acute myocardial infarction. (2016) (9)
- High RAD54B expression: an independent predictor of postoperative distant recurrence in colorectal cancer patients (2015) (9)
- Multicenter, randomized, controlled trial of S‐1 monotherapy versus S‐1 and interferon‐α combination therapy for hepatocellular carcinoma with extrahepatic metastases (2018) (9)
- Prognostic factors in non-small cell lung cancer patients with postoperative recurrence following third-generation chemotherapy. (2010) (9)
- Incidence of cancer-associated thromboembolism in Japanese gastric and colorectal cancer patients receiving chemotherapy: a single-institutional retrospective cohort analysis (Sapporo CAT study) (2019) (9)
- Feasibility study of cancer genome alterations identified by next generation sequencing: ABC study (2018) (9)
- Erlotinib for Non-Small Cell Lung Cancer with Leptomeningeal Metastases: A Phase II Study (LOGIK1101). (2020) (9)
- A phase I/II clinical trial for the hybrid of intracavitary and interstitial brachytherapy for locally advanced cervical cancer (2016) (8)
- A phase II study of atezolizumab for pretreated advanced/recurrent non-small cell lung cancer with idiopathic interstitial pneumonias: rationale and design for the TORG1936/AMBITIOUS study (2020) (8)
- A feasibility study of induction pemetrexed plus cisplatin followed by pleurectomy/decortication aimed at macroscopic complete resection for malignant pleural mesothelioma. (2013) (8)
- Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer (2020) (8)
- Placebo-controlled phase III study comparing dexamethasone on day 1 to on day 1-3 with NK1 receptor antagonist and palonosetoron in high emetogenic chemotherapy. (2016) (8)
- Economic analysis of palonosetron versus granisetron in the standard triplet regimen for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Japan (TRIPLE phase III trial) (2018) (8)
- PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer. (2016) (8)
- Validation of tissue factor pathway inhibitor 2 as a specific biomarker for preoperative prediction of clear cell carcinoma of the ovary (2021) (7)
- Comparison of the efficacies of first-generation epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced non-small-cell lung cancer harboring EGFR mutations (2018) (7)
- Detection of cytomegalovirus in urine samples by an enzyme-linked immunosorbent assay using a monoclonal antibody against the viral 150-kilodalton protein (1992) (7)
- Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016 (2018) (7)
- Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02). (2016) (7)
- Dynamic Modulation of Thymidylate Synthase Gene Expression and Fluorouracil Sensitivity in Human Colorectal Cancer Cells (2015) (7)
- Induction Chemoradiotherapy (50 Gy), Followed by Resection, for Stage IIIA-N2 Non-Small Cell Lung Cancer. (2018) (7)
- P-120 Prospective observational study monitoring circulating tumor DNA in resectable colorectal cancer patients undergoing radical surgery: GALAXY study in CIRCULATE-Japan (trial in progress) (2020) (7)
- Plasma high-mobility group box 1 as an indicator of surgical stress (2011) (7)
- Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations (2020) (7)
- Is a fecal occult blood test a useful tool for judging whether to perform capsule endoscopy in low-dose aspirin users with negative colonoscopy and esophagogastroduodenoscopy? (2017) (7)
- Sequential therapy of crizotinib followed by alectinib for non-small cell lung cancer harbouring anaplastic lymphoma kinase rearrangement (WJOG9516L): A multicenter retrospective cohort study. (2021) (7)
- Frequency and clinicopathological characteristics of biliary tract carcinomas harboring the FGFR2-fusion gene: A prospective observational study (PRELUDE study) (2019) (7)
- A Multicenter Phase II Trial of Docetaxel, Cisplatin, and Cetuximab (TPEx) Followed by Cetuximab and Concurrent Radiotherapy for Patients With Local Advanced Squamous Cell Carcinoma of the Head and Neck (CSPOR HN01: ECRIPS Study) (2019) (7)
- REVERCE: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan: Quality of life analysis. (2018) (7)
- 2015 Guidance on cancer immunotherapy development in early‐phase clinical studies (2015) (7)
- A randomized phase II study of TS-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for locally advanced non-small cell lung cancer (LA-NSCLC): WJOG 5008L. (2015) (7)
- Multiple Comparison (2011) (7)
- Histopathological factors affecting the extraction of high quality genomic DNA from tissue sections for next-generation sequencing. (2019) (6)
- Serum Heparan Sulfate Concentration is Correlated with the Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment in Patients with Lung Adenocarcinoma (2011) (6)
- Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPECCT and WJOG6510G (2020) (6)
- A phase I/II pharmacokinetics/pharmacodynamics study of irinotecan combined with S−1 for recurrent/metastatic breast cancer in patients with selected UGT1A1 genotypes (the JBCRG‐M01 study) (2017) (6)
- Feasibility of Laparoscopy-assisted Gastrectomy for Gastric Cancer in Elderly Patients: A Case-Control Study (2018) (6)
- Prospective observational study of the efficacy of nivolumab in Japanese patients with advanced melanoma (CREATIVE study) (2021) (6)
- Postoperative Pulmonary Embolism Including Asymptomatic Cases in Gynecologic Oncology (2009) (6)
- Carboplatin plus either docetaxel or paclitaxel for Japanese patients with advanced non-small cell lung cancer. (2013) (6)
- Survival analysis of a prospective multicenter observational study on surgical palliation among patients receiving treatment for malignant gastric outlet obstruction caused by incurable advanced gastric cancer (2020) (6)
- PARADIGM study: A multicenter, randomized, phase III study of 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer. (2016) (6)
- Hernia incidence following a randomized clinical trial of single-incision versus multi-port laparoscopic colectomy (2020) (6)
- A Randomized Phase III Study Comparing Carboplatin With Nab‐Paclitaxel Versus Docetaxel for Elderly Patients With Squamous‐Cell Lung Cancer: Study Protocol (2018) (6)
- Clinical outcome in patients with metastatic colorectal cancer harboring KRAS p.G13D mutation treated with cetuximab. (2011) (6)
- Rationale and design of a randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat in combination with cholestyramine for non-alcoholic fatty liver disease (2020) (5)
- A prospective, single-arm, multicenter trial of neoadjuvant chemotherapy with mFOLFOX6 plus panitumumab without radiotherapy for locally advanced rectal cancer (2020) (5)
- Comparing the effectiveness of magnesium oxide and naldemedine in preventing opioid-induced constipation: a proof of concept, single institutional, two arm, open-label, phase II, randomized controlled trial: the MAGNET study (2019) (5)
- Evaluation of FOLFOX or CAPOX reintroduction with or without bevacizumab in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy (REACT study) (2020) (5)
- A phase I/II study of nivolumab, paclitaxel, and ramucirumab as second-line in advanced gastric cancer. (2020) (5)
- The nationwide genomic screening project for gastrointestinal cancer in Japan (GI-SCREEN): Simultaneous identification of KRAS, NRAS, BRAF, and PIK3CA mutation in advanced colorectal cancer (aCRC) (GI-SCREEN 2013-01). (2015) (5)
- Japanese Lung Cancer Society Guideline for stage IV non-small cell lung cancer with epidermal growth factor receptor mutations (2021) (5)
- T-ACT (WJOG7112G): A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. (2017) (5)
- Meta-analysis of two randomized phase III trials (TCOG GI-0801 and ECRIN TRICS) of biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer (2019) (5)
- Randomized phase II trial of S‐1 plus cisplatin or docetaxel plus cisplatin with concurrent thoracic radiotherapy for inoperable stage III non‐small cell lung cancer (2020) (5)
- Effect of age, gender, and performance status (PS) on the duration results of adjuvant chemotherapy for stage III colon cancer: The IDEA collaboration. (2018) (5)
- A new nationwide genomic screening system in Japan for the development of targeted therapies against advanced non-small lung cancers with rare driver mutations. (2014) (5)
- Optimizing Sequential Treatment With EGFR Tyrosine Kinase Inhibitor With a Simulation of the T790M Mutation Rate in EGFR–Mutated Lung Cancer (2020) (5)
- A Comparative Study of Intravenous Injection Form and Oral Jelly Form of Alendronate Sodium Hydrate for Bone Mineral Disorder after Gastrectomy (2017) (4)
- aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal Cancer. (2018) (4)
- Efficacy of Video-assisted Thoracoscopic Esophagectomy for Stage II/III Esophageal Cancer: Analysis Using the Propensity Scoring System (2020) (4)
- Effect of melatonin and melatonin agonists on postoperative sleep quality in adult patients: a protocol for systematic review and meta-analysis with trial sequential analysis (2021) (4)
- Clinical impact of expanded BRAF mutational status on the outcome for metastatic colorectal cancer patients with anti-EGFR antibody: An analysis of the BREAC trial (Biomarker Research for Anti-EGFR Monoclonal Antibodies by Comprehensive Cancer Genomics). (2015) (4)
- Treatment Rationale and Design of a Phase III Study of Afatinib or Chemotherapy in Patients with Non-small-cell Lung Cancer Harboring Sensitizing Uncommon Epidermal Growth Factor Receptor Mutations (ACHILLES/TORG1834). (2020) (4)
- Plasma ICAM-1 (pICAM-1) and plasma IL-8 (pIL-8) level as biomarker of metastatic colorectal cancer patients (mCRC) treated with mFOLFOX6/XELOX plus bevacizumab (BV) (WJOG7612GTR). (2018) (4)
- Efficacy, safety, and tolerability of lubiprostone for the treatment of non-alcoholic fatty liver disease in adult patients with constipation: The LUBIPRONE, double-blind, randomised, placebo-controlled study design. (2018) (4)
- A Phase II Study of Nivolumab in Patients With Advanced Non–small‐cell Lung Cancer who Responded to Prior PD‐1/L1 Inhibitors: West Japan Oncology Group 9616L (WJOG9616L) (2019) (4)
- A randomized phase III study of continuous maintenance bevacizumab with or without pemetrexed after induction therapy with carboplatin (Car), pemetrexed (Pem), and bevacizumab (Bev) for advanced non-squamous non-small cell lung cancer (nSQ-NSCLC) without sensitizing EGFR mutations: The COMPASS study (2019) (4)
- LBA21_PRProspective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): Updated results of IDEA (International Duration Evaluation of Adjuvant chemotherapy) (2017) (4)
- A randomized phase II study of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab for previously untreated, liver-limited metastatic colorectal cancer that is unsuitable for resection (ATOM trial). (2018) (3)
- Randomized phase III study of nedaplatin (N) plus docetaxel (D) versus cisplatin (C) plus D for advanced or relapsed squamous cell carcinoma of the lung (SqLC): WJOG5208L. (2015) (3)
- Impact of the 12-gene recurrence score assay on deciding adjuvant chemotherapy for stage II and IIIA/B colon cancer: the SUNRISE-DI study (2021) (3)
- Observational study of first-line chemotherapy including cetuximab in patients with metastatic colorectal cancer: CORAL trial (2019) (3)
- Relationship between basal sodium intake and the effects of dapagliflozin in albuminuric diabetic kidney disease (2021) (3)
- Phase II study of erlotinib in advanced non-small cell lung cancer patients with leptomeningeal metastasis. (2016) (3)
- Response of nivolumab monotherapy in 124 Japanese patients with advanced melanoma: Interim analysis of prospective observational study (CREATIVE study) (2019) (3)
- Tegafur-Uracil Plus Gemcitabine Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer Previously Treated with Platinum (2008) (3)
- Sofosbuvir-based therapies associated with regression of liver fibrosis in patients with hepatitis C virus infection (2021) (3)
- REVIVE study: a prospective observational study in chemotherapy after nivolumab therapy for advanced gastric cancer. (2020) (3)
- 1291P A phase II study of nivolumab rechallenge therapy in advanced NSCLC patients who responded to prior anti-PD-1/L1 inhibitors: West Japan Oncology Group 9616L (2021) (3)
- An investigator initiated multicenter phase I/II study of paclitaxel, ramucirumab with nivolumab as the second-line treatment in patients with metastatic gastric cancer. (2018) (3)
- Monocyte nadir is a possible indicator for neutrophil nadir during lung cancer chemotherapy (2017) (3)
- The Lung Cancer Genomic Screening Project for Individualized Medicine in Japan (LC-SCRUM-Japan): Screening for RET and ROS1 fusions in advanced EGFR mutation-negative nonsquamous lung cancer and development of molecular targeted therapy. (2014) (3)
- Long-Term Clinical Outcomes After Filter Protection During Percutaneous Coronary Intervention in Patients With Attenuated Plaque - 1-Year Follow up of the VAMPIRE 3 (Vacuum Aspiration Thrombus Reemoval 3) Trial. (2020) (3)
- Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study (2017) (3)
- Randomized Phase II Study of Gemcitabine Monotherapy vs. Gemcitabine with an EPA-Enriched Oral Supplement in Advanced Pancreatic Cancer (2021) (3)
- Panitumumab versus cetuximab in patients with wild-type KRAS exon 2 metastatic colorectal cancer who received prior bevacizumab therapy: A combined analysis of individual patient data from ASPECCT and WJOG6510G. (2018) (3)
- Correction: A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer (2020) (3)
- Phase II clinical trial of S-1 plus oral leucovorin in previously treated patients with non-small-cell lung cancer. (2014) (3)
- Multicenter phase II trial of axitinib monotherapy for advanced biliary tract cancer refractory to gemcitabine-based chemotherapy (2019) (3)
- Real-World Evidence on Second-Line Treatment of Metastatic Colorectal Cancer Using Fluoropyrimidine, Irinotecan, and Angiogenesis Inhibitor. (2021) (3)
- Two phase III studies comparing 6 months of either mFOLFOX6 or XELOX with 3 months of the same regimen as adjuvant chemotherapy in patients with completely resected stage III colon cancer (ACHIEVE) or high-risk stage II colon cancer (ACHIEVE-2). (2014) (3)
- Randomized phase II trial of the prophylactic use of celecoxib for the prevention of oxaliplatin-related peripheral vascular pain in Capeox (YCOG1205) (2018) (3)
- Palmitate-induced lipotoxicity is crucial for the pathogenesis of nonalcoholic fatty liver disease in cooperation with gut-derived endotoxin (2018) (3)
- Outcome and Status of Microsatellite Stability in Japanese Atomic Bomb Survivors with Early Gastric Carcinoma (2013) (2)
- Radical prostatectomy as radical cure of prostate cancer in a high-risk group: A single-institution experience. (2013) (2)
- A phase II study of FOLFOXIRI with bevacizumab in untreated metastatic colorectal cancer patients: A UGT1A1 genotype and safety results (QUATTRO study). (2017) (2)
- Risk factors of chemotherapy-induced nausea and vomiting in patients with metastatic colorectal cancer: a prospective cohort study (YCOG1301) (2020) (2)
- REPLACEMENT trial in progress: Combination therapy with atezolizumab plus bevacizumab for TACE unsuitable patients with beyond up-to-seven criteria in intermediate stage hepatocellular carcinoma: A phase II study. (2021) (2)
- Early Tumor Shrinkage and Depth of Response in the Second-Line Treatment for KRAS exon2 Wild-Type Metastatic Colorectal Cancer: An Exploratory Analysis of the Randomized Phase 2 Trial Comparing Panitumumab and Bevacizumab in Combination with FOLFIRI (WJOG6210G) (2020) (2)
- A phase ΙI study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study) (2014) (2)
- 113TiP Prospective observational study monitoring circulating tumour DNA in resectable colorectal cancer patients undergoing radical surgery: GALAXY study in CIRCULATE-Japan (2020) (2)
- ACHIEVE-2 trial: A randomized phase III trial investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with high-risk stage II colon cancer (CC) (2019) (2)
- A randomized phase II trial evaluating CYP2D6 genotype-guided tamoxifen dosing in hormone receptor-positive metastatic breast cancer: TARGET-1. (2018) (2)
- Does primary site of colorectal cancer become a prognostic factor of patients undergoing curative resection of liver metastases (2017) (2)
- Neoadjuvant eribulin in early triple negative breast cancer (2018) (2)
- Correction to: Molecular detection and clinicopathological characteristics of advanced/recurrent biliary tract carcinomas harboring the FGFR2 rearrangements: a prospective observational study (PRELUDE Study) (2020) (2)
- A randomized multicenter phase II study of FOLFIRI plus either panitumumab (Pmab) or bevacizumab (Bmab) as second-line treatment for wild-type KRAS exon 2 metastatic colorectal cancer (mCRC) with exploratory biomarker analysis by liquid biopsy: WJOG6210G. (2016) (2)
- Factors predicting rubella vaccination among pregnant women in Japan: An interim report from the Pregnant Women Health Initiative. (2020) (2)
- Relationship between sleep-disordered breathing and renal dysfunction in acute coronary syndrome. (2018) (2)
- Erratum to: Impact of intra-abdominal absorbable sutures on surgical site infection in gastrointestinal and hepato-biliary-pancreatic surgery: results of a multicenter, randomized, prospective, phase II clinical trial (2017) (2)
- Non-small cell lung cancer, early stage (2012) (2)
- Randomized Phase II Study of Adjuvant Chemotherapy with S-1 Versus CDDP + S-1 in Resected Stage II-IIIA Non-Small-Cell Lung Cancer (WJOG4107) (2012) (2)
- A phase 2 study of fosaprepitant combined with high-dose dexamethasone for Japanese cancer patients receiving highly emetogenic chemotherapy (2018) (2)
- The Nationwide Cancer Genome Screening Projects for Gastrointestinal Cancer in Japan (SCRUM-Japan GI-SCREEN): Efficient identification of actionable cancer genome alterations in advanced colorectal and non-colorectal gastrointestinal cancer (GI Screen 2013-01-CRC and 2015-01-Non CRC). (2015) (2)
- Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first‐line treatment for metastatic colorectal cancer: Safety lead‐in results from the QUATTRO-II study (2021) (2)
- An international phase III randomized, non-inferiority trial comparing 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy for colon cancer: Compliance and safety of the phase III Japanese ACHIEVE trial. (2016) (2)
- WJOG6110B (ELTOP): Randomized phase II trial comparing trastuzumab plus capecitabine (HX) and lapatinib plus capecitabine (LX) in HER2-positive metastatic breast cancer patients previously treated with trastuzumab and taxanes. (2012) (2)
- A Multicenter Feasibility Study of EBUS-TBNA for Potentially Operable Non-Small Cell Lung Cancer: The JMTO LC07-02 Study (UMIN000001280) (2016) (1)
- P4-10 The impact of neutrophil/lymphocyte ratio (NLR) on overall survival for patients with metastatic colorectal cancer (2021) (1)
- PD-012Validation study of the 12-gene Recurrence Score (RS) in patients (pts) with stage II and III colon cancer (CC) without adjuvant chemotherapy; SUNRISE Study (2015) (1)
- Identification of Serum Prognostic Biomarkers of Severe COVID-19 by Multi-Layered Quantitative Proteomic Approach (2020) (1)
- Randomized phase II study of regorafenib followed by cetuximab versus reverse sequence for wild-type KRAS metastatic colorectal cancer previously treated with fluoropyrimidine, oxaliplatin, and irinotecan (REVERCE). (2014) (1)
- 450P The impact of late-line treatment on overall survival (OS) from the initiation of first-line chemotherapy (CT) for patients (pts) with metastatic colorectal cancer (mCRC): Updated analysis (2020) (1)
- The short-term outcomes from TOP-G trial: Ramdomized phase II noninferiority trial comparing gastrectomy with omentectomy and omentum preserving gastrectomy for advanced gastric cancer. (2020) (1)
- Projecting Event-Based Analysis Dates in Clinical Trials: An Illustration Based on the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) Collaboration. Projecting Analysis Dates for the IDEA Collaboration (2014) (1)
- Randomized phase II study of S-1 monotherapy versus gemcitabine plus S-1 in gemcitabine-refractory advanced pancreatic cancer. (2017) (1)
- 626PPROGNOSTIC IMPACT OF HER2, EGFR, AND C-MET STATUS ON OVERALL SURVIVAL OF ADVANCED GASTRIC CANCER PATIENTS TREATED WITH STANDARD CHEMOTHERAPY WITHOUT TRASTUZUMAB IN A FIRST-LINE TREATMENT: A JAPANESE MULTICENTER COLLABORATIVE RETROSPECTIVE STUDY. (2014) (1)
- The ATOM trial: A multicenter, randomized phase II study of modified FOLFOX6 plus bevacizumab and modified FOLFOX6 plus cetuximab for colorectal cancer with liver-limited metastases. (2016) (1)
- Prognostic impact of human epidermal growth factor-2 (HER2) status on overall survival (OS) of advanced gastric cancer (AGC) patients (pts) treated with standard chemotherapy without trastuzumab as a first-line treatment: A Japanese multicenter collaborative retrospective study. (2013) (1)
- P1.03-027 Randomized Phase 2 Study Comparing CBDCA+PTX+BEV and CDDP+PEM+BEV in Treatment-Naïve Advanced Non-Sq NSCLC (CLEAR Study) (2017) (1)
- Impact of treatment with bevacizumab beyond disease progression: a randomized phase II study of docetaxel with or without bevacizumab after platinum-based chemotherapy plus bevacizumab in patients with advanced nonsquamous non–small cell lung cancer (WJOG 5910L) (2012) (1)
- 1285P Final analysis of TORG1936/AMBITIOUS: Phase II study of atezolizumab for pretreated non-small cell lung cancer with idiopathic interstitial pneumonia (2021) (1)
- A multicenter phase II trial of docetaxel, cisplatin and cetuximab (TPE) followed by cetuximab concurrent with radiotherapy in patients with local advanced squamous cell carcinoma of the head and neck (ECRIPS study). (2017) (1)
- Predictive value of chemotherapy-induced neutropenia for drug efficacy in advanced gastric carcinoma: Analysis of prospective nationwide survey (2007) (1)
- 2168 Predictive biomarker analysis of early tumor shrinkage induced by FOLFIRI+Bev for patients with metastatic colorectal cancer in WJOG4407G study (2015) (1)
- A randomized phase III trial of skin closure by subcuticular suture versus skin stapler to prevent incisional surgical site infection after elective colorectal cancer surgery: results of the subcuticular suture against infection (SSI) study (2014) (1)
- OA02.06 The Sequential Therapy of Crizotinib Followed by Alectinib: Real World Data of 840 Patients with NSCLC Harboring ALK-Rearrangement (WJOG9516L) (2019) (1)
- Randomized phase II study comparing cisplatin + pemetrexed + bevacizumab with carboplatin + paclitaxel + bevacizumab in treatment-naïve advanced non-squamous non-small cell lung cancer (CLEAR study). (2018) (1)
- P1.01-33 Randomized Phase 2 Study Comparing CBDCA+PTX+BEV and CDDP+PEM+BEV in Treatment-Naïve Advanced Non-Sq NSCLC (CLEAR study) (2018) (1)
- Phase III Study of Cisplatin Plus Pemetrexed versus Cisplatin Plus Vinorelbine for Completely Resected Stage II-IIIA Non-Squamous Non-Small-Cell Lung Cancer: The JIPANG Study (2019) (1)
- Phase I/II study of carboplatin plus weekly nab-paclitaxel in patients aged ≥75 years with squamous-cell lung cancer: TORG1322. (2020) (1)
- Multicenter Phase II Trial of Axitinib Monotherapy for Gemcitabine-Based Chemotherapy Refractory Advanced Biliary Tract Cancer (AX-BC Study). (2020) (1)
- Clinical utility of quasimonomorphic variation range (QMVR) on the determination of microsatellite instability (MSI) status in Japanese patients (pts) with colorectal cancer (CRC): GI-SCREEN-CRC-MSI sub-study 01. (2017) (1)
- 9032 POSTER A Feasibility Study of Induction Pemetrexed Plus Cisplatin Followed by Extrapleural Pneumonectomy (EPP) and Postoperative Hemithoracic Radiation (H-RT) for Malignant Pleural Mesothelioma (MPM) – First All Japan Trial (2011) (1)
- Topoisomerase II, carbonyl reductase I, and chemosensitivity for amrubicin in the treatment of patients with small-cell lung cancer. (2009) (1)
- Vascular endothelial growth factor (VEGF)-D and clinical outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with second-line FOLFIRI plus bevacizumab (Bev): A biomarker study of the WJOG 6210G trial. (2020) (1)
- SUNRISE-DI study: decision impact of the 12-gene recurrence score (12-RS) assay on adjuvant chemotherapy recommendation for stage II and IIIA/B colon cancer. (2019) (1)
- Tu1786 The Safety of Stapler Versus Non-Stapler Closure of the Pancreatic Remnant After Distal Pancreatectomy: A Multicenter Randomized Controlled Trial (2015) (1)
- Influence of treatment with prior bevacizumab: A combined analysis of individual patient data from ASPECCT and WJOG6510G trial which compared panitumumab versus cetuximab in patients with wild-type KRAS exon 2 metastatic colorectal cancer. (2018) (1)
- Phase III randomised trial comparing 6 vs. 12-month of capecitabine as adjuvant chemotherapy for patients with stage III colon cancer: final results of the JFMC37-0801 study (2019) (1)
- Efficacy of PD-1 Inhibitors in Older Non-small Cell Lung Cancer Patients (2020) (1)
- Predictive biomarker analysis of early tumor shrinkage induced by FOLFIRI+Bev for patients with metastatic colorectal cancer in WJOG4407G study. (2015) (1)
- 9117 POSTER Randomized Phase II Trial of Zoledronic Acid in Combination With Docetaxel in Previously Treated Non-small Cell Lung Cancer (NSCLC) Patients With Bone Metastases – Result of a West Japan Oncology Group Study (2011) (1)
- Randomized controlled trial of landiolol, a short-acting beta-1 adrenergic receptor blocker, illustrating changes in high-molecular weight adiponectin levels after elective percutaneous coronary intervention (2020) (1)
- Three-year outcomes of two phase II studies of adjuvant chemotherapy with S-1 plus oxaliplatin or capecitabine plus oxaliplatin in patients with stage III gastric cancer after D2 gastrectomy. (2018) (1)
- O-21 METABEAM study: Combined analysis of concordance studies between liquid and tissue biopsies for RAS mutations in colorectal cancer patients with single metastatic sites (2020) (1)
- 3079 Randomized phase II trial of amrubicin plus irinotecan versus cisplatin plus irinotecan in chemo-naïve patients with extensivedisease small-cell lung cancer: Results of the Japan Multinational Trial Organization (JMTO) LC 08-01 (2015) (1)
- Early-onset stage II/III colorectal adenocarcinoma in the IDEA database: Treatment adherence, toxicities, and outcomes from adjuvant fluoropyrimidine and oxaliplatin. (2021) (1)
- A feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy (EPP) and postoperative hemithoracic radiation (H-RT) for malignant pleural mesothelioma (MPM): First all-Japan trial. (2013) (1)
- Randomized phase II trial of S-1 plus cisplatin or docetaxel plus cisplatin with concurrent thoracic radiotherapy for inoperable stage III non-small cell lung cancer (TORG1018). (2017) (1)
- What are the True Advantages of Devices for Hepatic Parenchymal Transection in Open Surgery? Reply (2015) (1)
- A phase II study of everolimus in patients with unresectable pancreatic neuroendocrine carcinoma refractory or intolerant to platinum-containing chemotherapy. (2018) (1)
- Reply to: “Multimodal Treatment of Locally Advanced Gastric Cancer: Will the West Meet the East?”, by Marino, Elisabetta et al. (2019) (1)
- Sunitinib Alone or after Nephrectomy in Renal Cancer. (2018) (1)
- 515PRandomized phase II study of TJ-54 (Yokukansan) for postoperative delirium in gastrointestinal and lung malignancy patients (2017) (1)
- A Nationwide Survey of Adult T-Cell Leukemia/Lymphoma (ATL) Newly Diagnosed Over the Last Decade in Japan (2012) (1)
- Analysis of early tumor shrinkage (ETS) and depth of response (DpR) in metastatic colorectal cancer (mCRC) patients (pts) treated with second-line FOLFIRI plus panitumumab (Pani) or bevacizumab (Bev): Results from a randomized phase II WJOG6210G trial. (2020) (1)
- 579PPrimary efficacy results and clinical impact of UGT1A1 genotype on safety from a Phase II study of FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer: The QUATTRO study (2017) (1)
- A randomized phase III study comparing carboplatin with nab-paclitaxel versus docetaxel for elderly patients with squamous-cell lung cancer: Capital study. (2021) (1)
- Abstract P4-21-14: A randomized phase II trial of trastuzumab + capecitabine versus lapatinib + capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP (2017) (1)
- Survival update in randomized phase II trial of S-1/cisplatin (SP) or docetaxel/cisplatin (DP) with concurrent thoracic radiotherapy for inoperable stage III non-small cell lung cancer (NSCLC)-TORG1018. (2018) (1)
- Meta-analysis of patient-level data on biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer with the TCOG GI-0801 BIRIP and ECRIN TRICS RCTs: protocol paper (2017) (1)
- Impact of Serum HGF on Treatment Response to EGFR Tyrosine Kinase Inhibitors in Patients with Non-Small-Cell Lung Adenocarcinoma (2010) (1)
- Randomized phase II study of carboplatin plus either docetaxel (CbD) or paclitaxel (CbP) in Japanese patients with advanced non-small cell lung cancer (NSCLC): JMTO LC07-01. (2010) (1)
- Identification of Serum Prognostic Biomarkers of Severe COVID-19 by Quantitative Proteomic Approach (2021) (0)
- 1551PRisk factors of chemotherapy-induced nausea and vomiting during cisplatin regimen in antiemetic triplet regimen including palonosetron or granisetron: TRIPLE study (phase lll) (2017) (0)
- A randomized phase II study to assess trastuzumab beyond progression in HER2-positive advanced gastric cancer: WJOG7112G. (2018) (0)
- Abstract 1974: Clonal and subclonal mutational landscapes in circulating tumor DNA in metastatic colorectal cancer: An exploratory analysis from the phase III PARADIGM study (2020) (0)
- P25.02 Concurrent Chemoradiotherapy With Cisplatin + S-1 for Locally Advanced Non-Small Cell Lung Cancer: IPD Meta-Analysis (2021) (0)
- 421P Upfront chemotherapy vs. surgery for very low lying locally advanced rectal cancer without preoperative chemoradiation: The NAIR phase II/III trial (2020) (0)
- O-010An international phase III randomized, non-inferiority trial comparing 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy for colon cancer: compliance and safety of the phase III Japanese ACHIEVE trial (2016) (0)
- Predictive value of serum HGF for treatment response to EGFR tyrosine kinase inhibitor in patients with lung adenocarcinoma. (2010) (0)
- 163MO Randomized phase II study of eribulin-based neoadjuvant chemotherapy for triple-negative primary breast cancer patients stratified by homologous recombination deficiency status (JBCRG-22) (2020) (0)
- Low‐density‐lipoprotein apheresis‐mediated endothelial activation therapy to severe‐peripheral artery disease study: Rationale and study design (2020) (0)
- Abstract P1-01-20: Clinicopathlogic Analysis of Invasive Breast Carcinoma with Micropapillary Component (2012) (0)
- 2158 The Nationwide Cancer Genome Screening Project for Gastrointestinal Cancer in Japan (GI-SCREEN): Simultaneous identification of KRAS, NRAS, BRAF, and PIK3CA mutation in advanced colorectal cancer (aCRC) (GI-SCREEN 2013-01) (2015) (0)
- P-77 Real-world evidence on second-line treatment of fluoropyrimidine, irinotecan, and anti-VEGF antibody for metastatic colorectal cancer (2020) (0)
- A Phase II Study of S-1 (S) Plus Cisplatin (P) with Concurrent Thoracic Radiotherapy (TRT) for Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC) West Japan Oncology Group (WJOG) 3706 Trial | 文献情報 | J-GLOBAL 科学技術総合リンクセンター (2010) (0)
- Title Oral and Parenteral Versus Parenteral Antibiotic Prophylaxis in Elective Laparoscopic Colorectal Surgery (JMTO PREV (2019) (0)
- 1429 POSTER FCGRIIa-131 and FCGRIIIa-158 Polymorphisms – Distribution and Clinical Outcomes of Cetuximab-based Chemotherapy in Japanese Patients With Metastatic Colorectal Cancer (mCRC) (2011) (0)
- P-160 A phase II study of resection followed capecitabine plus oxaliplatin for liver metastasis of colorectal cancer (REX study): Safety analysis (2020) (0)
- The relation between postoperative surgical complications and gastric cancer survival (2017) (0)
- Prospective multicenter study of the impact of the 12-gene assay recurrence score on adjuvant chemotherapy treatment recommendations for stage II/III colon cancer in the post-IDEA era: SUNRISE-Decision Impact study. (2018) (0)
- 1188P Concurrent chemoradiotherapy with cisplatin + S-1 for locally advanced non-small cell lung cancer: IPD meta-analysis (2021) (0)
- ISY-17-2UGT1A1 genotype as an indicator of neutropenia for FOLFOXIRI with bevacizumab in patients with mCRC (QUATTRO study) (2016) (0)
- Comparison of the efficacies of first-generation epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced non-small-cell lung cancer harboring EGFR mutations (2018) (0)
- Stapled vs hand-sewn anastomosis of duodenojejunostomy in pylorus-preserving pancreaticoduodenectomy: a randomized controlled trial (2014) (0)
- Phase II study of atezolizumab for pretreated advanced / recurrent non-small cell lung cancer with idiopathic interstitial pneumonia (TORG1936 / AMBITIOUS study) (2019) (0)
- The safety assessment of crizotinib and alectinib from real-world data of 840 ALK-inhibitor naïve patients with NSCLC harboring ALK-rearrangement (WJOG9516L) (2019) (0)
- Evaluation of the re-introducing FOLFOX or XELOX ± bevacizumab in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy (REACT study). (2019) (0)
- Plasma VEGF-A (pVEGF-A) level in efficacy analysis of metastatic colorectal cancer patients (mCRC) treated with mFOLFOX6/XELOX plus bevacizumab (BV) (WJOG7612GTR). (2018) (0)
- Time-dependent change in relapse sites of renal cell carcinoma after curative surgery (2018) (0)
- A multi-institutional feasibility study of induction pemetrexed (Pem) plus cisplatin (Cis) followed by extrapleural pneumonectomy (EPP) and postoperative hemithoracic radiation (RT) for malignant pleural mesothelioma (MPM): Japan Mesothelioma Research Center (JMRC) 001001 trial. (2010) (0)
- A multicentre, prospective clinical evaluation study for analyzing RAS mutational status utilizing plasma circulating tumor DNA in patients with metastatic colorectal cancer. (2018) (0)
- Author's response to reviews Title:Clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer Authors: (2015) (0)
- SUNRISE-DI Study: Decision Impact of the 12-Gene RS Assay on Adjuvant Chemotherapy for Stage II and IIIA/B Colon Cancer (2019) (0)
- Survival outcome in HER2-amplified metastatic colorectal cancer (mCRC). (2018) (0)
- [Using Real World Data in Cancer Clinical Studies]. (2020) (0)
- P1-184Feasibility study of nivolumab and docetaxel in previously treated patients with advanced non-small cell lung cancer (2017) (0)
- OA12.02 Randomized Phase II Study of CDDP+S-1 vs CDDP+PEM Combined with Thoracic RT for Locally Advanced Non-Sq NSCLC: SPECTRA Study (2019) (0)
- Meta-analysis of biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer. (2018) (0)
- Quattro-II study: A multicenter randomized phase II study comparing capoxiri plus bevacizumab with FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer as the first-line treatment. (2020) (0)
- In conclusion, ATL-PI is a PI for patients with aggressive ATL, anditisapplicableforbothacuteandlymphomatypesseparately.We believeATL-PIisapromisingtoolforriskstratification.Wehopethat it will be validated internationally in studies that include patients treated with a combination of interferon alfa (2012) (0)
- A Multiinstitutional Feasibility Study of Trimodality Therapy for Resectable Malignant Mesothelioma (2009) (0)
- GS-01-Efficacy, safety, and tolerability of lubiprostone for the treatment of non-alcoholic fatty liver disease: The LUBIPRONE, doubleblind, randomized, placebo-controlled, phase II study (2019) (0)
- MA 17.06 Safety Data from Randomized Phase II Study of CDDP+S-1 vs CDDP+PEM Combined with TRT for Locally Advanced Non-Squamous NSCLC (2017) (0)
- [Current status and future direction of Japan's clinical trial for malignant pleural mesothelioma]. (2011) (0)
- Points to Consider on Clinical Trials Act in Japan (2020) (0)
- Allogeneic Peripheral Blood Stem Cell Transplantation Using Reduced-Intensity Conditioning Regimen with Fludarabine and Busulfan from HLA-Matched Related Donor for Elderly Adult T-Cell Leukemia/Lymphoma: Results of Multicenter Phase II Study (ATL-NST-3) (2014) (0)
- INACTIVE ALDEHYDE DEHYDROGENASE 2 IS AN INDEPENDENT RISK OF PANCREATIC CANCER IN A JAPANESE POPULATION (2006) (0)
- 415P Prognostic effect of postoperative serum carcinoembryonic antigen (CEA) combined with T4 versus T3 tumors in patients with high-risk stage 2 colon cancer: ACHIEVE-2 phase III randomized clinical trial (2020) (0)
- Abstract #LB-302: Computational identification of oncogenic and tumor suppressor gene networks that related to the cell cycle regulation (2009) (0)
- 401MO OS and long-term DFS with 3- vs. 6-month adjuvant oxaliplatin and fluoropyrimidine-based therapy for stage III colon cancer patients: A randomized phase III ACHIEVE trial (2020) (0)
- 1227PDNATIONWIDE GENOMIC SCREENING FOR RET FUSION IN ADVANCED EGFR MUTATION-NEGATIVE NON-SQUAMOUS LUNG CANCER AND DEVELOPMENT OF MOLECULAR TARGETED THERAPY IN JAPAN: LC-SCRUM-JAPAN. (2014) (0)
- JIPANG study: Randomized phase III study of pemetrexed/cisplatin (PEM/Cis) versus vinorelbine /cisplatin (VNR/Cis) for completely resected p-stage II-IIIA non-squamous non-small cell lung cancer (Ns-NSCLC): Outcomes based on EGFR mutation status (2019) (0)
- A Prospective Feasibility Trial of Unrelated Bone Marrow Transplantation with Reduced Intensity Conditioning Regimen for Elderly Patients with Adult T-Cell Leukemia/Lymphoma (ATL), (2011) (0)
- Age, gender, and performance status effects on efficacy of 3 versus 6 months of adjuvant oxaliplatin and fluoropyrimidine chemotherapy for stage III colon cancer: Phase III ACHIEVE trial as part of the IDEA collaboration. (2018) (0)
- 1307PA NATIONWIDE GENOMIC SCREENING SYSTEM IN JAPAN FOR THE DEVELOPMENT OF MOLECULAR TARGETED THERAPIES AGAINST NON-SMALL CELL LUNG CANCERS WITH RARE DRIVER MUTATIONS. (2014) (0)
- 455 Postoperative Upstaging and Sentinel Lymph Node Metastasis in Patients with Ductal Carcinoma in Situ Diagnosed by Needle Biopsy (2012) (0)
- Simultaneous identification of 36 mutations in KRAS codons 61and 146, BRAF, NRAS, and PIK3CAin a single reaction by multiplex assay kit (2013) (0)
- The impact of late-line treatment on overall survival (OS) from the initiation of first-line chemotherapy (CT) for patients (pts) with metastatic colorectal cancer (mCRC) (2019) (0)
- Distributions of FcγRIIa-131 and FcγRIIIa-158 polymorphisms and clinical response to cetuximab in Japanese patients with metastatic colorectal cancer (mCRC). (2011) (0)
- O-16 Relative impact of T4 and N2 on the efficacy of 3 versus 6 months of adjuvant CAPOX for high-risk stage II and stage III colon cancer: ACHIEVE and ACHIEVE-2 trials (2020) (0)
- Reply to J.J. Castillo et al (2012) (0)
- The influence of biliary drainage in patients with advanced pancreatic cancer receiving FOLFIRINOX. (2018) (0)
- Efficacy of Lubiprostone in Patients with Non-Alcoholic Fatty Liver Disease: A Randomized, Double-Blind, Placebo-Controlled, Phase 2A Trial (2020) (0)
- Tissue factor pathway inhibitor II as a specific biomarker for pre-operative prediction of clear-cell carcinoma of the ovary. (2020) (0)
- A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer (2019) (0)
- Phase I/II study of S-1 combined with gemcitabine in elderly patients with advanced non-small cell lung cancer: Thoracic Oncology Research Group (TORG) 0502 (2008) (0)
- 159PDNeoadjuvant therapy with trastuzumab emtansine and pertuzumab in patients with HER2-positive primary breast cancer (A randomized, phase 2 study; JBCRG-20) (2017) (0)
- Abstract 2052: Tumor mutation burden as a biomarker of relapse free survival of non-squamous non-small cell lung cancer treated with PEM/CDDP in adjuvant setting (the JIPANG-TR) (2020) (0)
- ATOM trial: a randomized phase II study of mFOLFOX6+Bmab vs. mFOLFOX6+Cmab for not-optimary resectable KRAS wt mCRC. (2018) (0)
- 519MO Concordance analysis of treatment recommendations between central consensus and multidisciplinary tumor boards (2021) (0)
- Effectiveness of Acyclovir Prophylaxis Against Varicella Zoster Virus Infection after Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis (2017) (0)
- Title Evaluating the 21-gene assay Recurrence Score ® as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer (2018) (0)
- The safety of liver surgery with no-drain policy: a multicenter randomized controlled trial (2018) (0)
- Impact of high-risk features on disease-free survival (DFS) in patients (pts) with high-risk stage II colon cancer (CC) in ACHIEVE-2 trial as part of the IDEA collaboration. (2020) (0)
- MIS2. lung cancer clinical (2012) (0)
- Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial) (2019) (0)
- 567PClinical utility of quasi-monomorphic variation range (QMVR) on the determination of microsatellite instability (MSI) status in patients (pts) with colorectal cancer (CRC): GI-SCREEN-CRC-MSI sub-study 01 (2017) (0)
- Randomized Phase II Trial of Zoledronic Acid in Combination with Docetaxel in Previously Treated Non-Small-Cell Lung Cancer (NSCLC) Patients with Bone Metastases: WJTOG3806 (2012) (0)
- Importance of CDK7 for G1 Re-Entry into the Mammalian Cell Cycle and Identification of New Downstream Networks Using a Computational Method (2010) (0)
- An analysis of serum heparan sulfate concentration and EGFR tyrosine kinase inhibitor treatment in patients with non-small cell lung adenocarcinoma. (2011) (0)
- 1470PTHE EFFECT OF PROPHYLACTIC CRANIAL IRRADIATION (PCI) IN THE PATIENTS WITH EXTENSIVE-DISEASE SMALL-CELL LUNG CANCER (ED-SCLC): RESULTS OF A JAPANESE RANDOMIZED PHASE III TRIAL. (2014) (0)
- [PRIMER FOR SURGICAL CLINICAL TRIALS]. (2016) (0)
- 445P Real-world evidence (RWE) on the clinical outcomes in 1st-line chemotherapy (CT) for fit and vulnerable patients (pts) with metastatic colorectal cancer (mCRC) (2020) (0)
- The impact of sequential therapy of crizotinib followed by alectinib: Real-world data analysis of 840 ALK-inhibitor naïve patients with NSCLC harboring ALK-rearrangement (WJOG9516L). (2019) (0)
- Bevacizumab plus platinum-based chemotherapy in advanced non-squamous non-small-cell lung cancer: a randomized, open-label phase 2 study (CLEAR) (2021) (0)
- SAT-286 EFFECT OF DAPAGLIFLOZIN ON URINARY ALBUMIN EXCRETION AND HOME BLOOD PRESSURE PARAMETERS IN JAPANESE TYPE 2 DIABETES MELLITUS PATIENTS WITH ALBUMINURIA: Y-AIDA STUDY (2019) (0)
- Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016 (2018) (0)
- Association of postoperative serum carcinoembryonic antigen (CEA) with disease-free survival in patients with stage III colon cancer: ACHIEVE phase III randomized clinical trial. (2020) (0)
- P-18 REMARRY and PURSUIT trials: Liquid biopsy-guided re-challenge of anti-EGFR monoclonal antibody for patients with RAS/BRAF V600E wild-type metastatic colorectal cancer (2020) (0)
- P2-307: Patients with adenocarcinoma and non-smoking had better survival in chemotherapy of gemcitabine plus oral UFT for advanced non-small-cell-lung cancer previously treated with platinum (2007) (0)
- Biomarker analyses of Asian women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) receiving ribociclib (RIB) + endocrine therapy (ET). (2018) (0)
- 1766P Longitudinal alteration of cytokine profile in the peripheral blood and clinical response for neoadjuvant chemotherapy in triple-negative breast cancer patients (translational research of the JBCRG-22 trial) (2021) (0)
- P2.07-042 Feasibility Study of Nivolumab and Docetaxel in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer (2017) (0)
- REVIVE study: Prospective observational study of efficacy and safety in chemotherapy (CTx) after progressive disease of nivolumab (NIV) therapy for metastatic gastric cancer (mGC). (2019) (0)
- non-small cell lung cancer, early stage 1179O THE EUROPEAN THORACIC ONCOLOGY PLATFORM LUNGSCAPE PROJECT: A WAY TO BRIDGE NON-SMALL CELL LUNG CANCER MOLECULAR CHARACTERISTICS AND CLINICAL DATA (2012) (0)
- Multicenter Phase II Trial of Axitinib Monotherapy for Gemcitabine-Based Chemotherapy Refractory Advanced Biliary Tract Cancer (AX-BC Study) Clinical Trial Results (2021) (0)
- Randomized phase II study of TJ-54 (Yokukansan) for postoperative delirium in gastrointestinal malignancy patients. (2017) (0)
- A randomised phase II trial of S-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for unresectable, locally advanced non-small cell lung cancer: WJOG5008L (2018) (0)
- REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer (2021) (0)
- Quadruplet regimen with capecitabine, irinotecan, oxaliplatin, and bevacizumab in chemo-naive patients with metastatic colorectal cancer: Results from the safety lead-in of QUATTRO-II study. (2021) (0)
- O2-18-2Risk factors of CINV induced by CDDP in antiemetic triplet regimen including palonosetron or granisetron: TRIPLE study (2017) (0)
- Abstract 2208: Detection of somatic mutations and gene amplifications using amplicon sequencing with biopsy samples from patients with advanced gastric cancer (2014) (0)
- Impact of first-line bevacizumab (BV) on the clinical outcomes of patients with metastatic colorectal cancer (mCRC) treated with second-line FOLFIRI plus BV. (2014) (0)
- Patient-specific meta-analysis of 3 validation studies of the 12-gene colon cancer recurrence score assay for recurrence risk assessment after surgery with or without 5FU and oxaliplatin. (2021) (0)
- Gemcitabine plus nab-paclitaxel versus gemcitabine alone in elderly patients aged 76 years or older with unresectable pancreatic cancer: A propensity score-matched multicenter prospective observational study. (2021) (0)
- P2810Clinical outcomes 1 year after filter protection during percutaneous coronary intervention in patients with attenuated plaque identified by intravascular ultrasound (2019) (0)
- Biomarker analysis of WJOG4107, a randomized phase II trial of adjuvant chemotherapy with S-1 versus CDDP+S-1 for resected stage II-IIIA non-small cell lung cancer (NSCLC). (2013) (0)
- 1292PSafety data from randomized phase II study of cisplatin (CDDP)+S-1 versus CDDP+pemetrexed (PEM) combined with thoracic radiotherapy (TRT) for locally advanced non-squamous (non-sq) non-small cell lung cancer (NSCLC): SPECTRA study (2017) (0)
- O2-2-3Randomized Phase II Trial Comparing CDDP+TS-1+TRT and CDDP+DTX+TRT in Locally Advanced NSCLC (TORG1018) (2017) (0)
- P2.02-027 A Randomized Phase II Trial of S-1 plus Cisplatin or Docetaxel plus Cisplatin with Concurrent Thoracic Radiotherapy for Stage III NSCLC: TORG1018: Topic: Multimodality Treatment (2017) (0)
- Abstract CT164: Circulating tumor DNA analysis for predictive and prognostic factors in patients with metastatic colorectal cancer: An exploratory analysis from the phase III PARADIGM study (2018) (0)
- SY17-5 Potential biomarkers for immunotherapy of gastric cancer (2021) (0)
- 1333P Dose and schedule modifications of carboplatin plus nab-paclitaxel for elderly patients with squamous non-small cell lung cancer from the CAPITAL study (2021) (0)
- Clinicopathological characteristics and impact on efficacy of three versus six months of adjuvant chemotherapy in early-onset colon cancer: ACHIEVE and ACHIEVE-2 trials. (2021) (0)
- Carboplatin (Cb) plus nab-paclitaxel (PTX) versus docetaxel (D) for elderly squamous (Sq) non-small cell lung cancer (NSCLC) (CAPITAL study) (2016) (0)
- P2.06-037 A Feasibility Study of Concurrent Chemoradiation Followed by Surgery for Pathologically-Proven Clinical IIIA-N2 Non-Small Cell Lung Cancer: Topic: Radiotherapy, TT Fields (2017) (0)
- Neutrophil-to-lymphocyte ratio is a prognostic marker in bladder cancer patients after radical cystectomy (2016) (0)
- PO-0686: A feasibility study of induction CDDP/MTA followed by EPP and postoperative hemithoracic radiation therapy for MPM (2014) (0)
- Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies (2020) (0)
- Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer (2020) (0)
- OA02.04 Phase II Trial of Antiemetic Oral Granisetron Plus Dexamethasone for Nausea and Vomiting Caused by Crizotinib in ALK or ROS1 Fusion-Positive NSCLC (2021) (0)
- Phase I/II study of oral TS-1 and gemcitabine in elderly patients with advanced non-small cell lung cancer (NSCLC): Thoracic Oncology Research Group 0502 (2007) (0)
- Economic analysis of palonosetron versus granisetron in the standard triplet regimen for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Japan (TRIPLE phase III trial) (2018) (0)
- 465 Detection of somatic mutations and gene amplification using Oncomine Cancer Research Panel with biopsy samples from patients with advanced gastric cancer (2015) (0)
- Ribociclib (RIB) + endocrine therapy (ET) in Japanese women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC). (2018) (0)
- Rationale and protocol design for the TORG1835/NEXT-SHIP study: a phase II study of carboplatin, etoposide and nintedanib for unresectable limited/extensive disease small cell lung cancer with idiopathic pulmonary fibrosis (2020) (0)
- A survival analysis of a prospective multicenter observational study of surgical palliation in patients treated for malignant gastric outlet obstruction caused by incurable advanced gastric cancer. (2018) (0)
- O3–096BIOMARKER ANALYSIS OF WJOG4107 (A RANDOMIZED PHASE II TRIAL OF ADJUVANT CHEMOTHERAPY WITH S-1 VS CDDP + S-1 IN NSCLC) (2013) (0)
- Abstract P2-05-24: Prognostic value of circulatingPIK3CAmutations revealed with digital PCR in patients with HER2-positive advanced breast cancer: Results of West Japan Oncology Group study 6110BTR (2017) (0)
- Phase I/II pharmacokinetics/pharmacodynamics study of irinotecan and S-1 for recurrent/metastatic breast cancer in patients with select UGT1A1 genotypes (the JBCRG-M01 study) (2016) (0)
- O2-3-2LURET study: A phase II study of vandetanib, RET inhibitor in patients with advanced RET fusion-positive NSCLC (2015) (0)
- Efficacy and Safety of Carboplatin With Nab-Paclitaxel Versus Docetaxel in Elderly Patients with Squamous-Cell Lung Cancer (CAPITAL): A Randomized, Multicenter, Open-Label, Phase III Trial (2021) (0)
- 104P Angiogenesis-related factors and clinical outcomes in combination therapy with paclitaxel (PTX), ramucirumab (RAM) plus nivolumab (Nivo) for advanced gastric cancer (AGC) (2020) (0)
- 499P The safety and efficacy of edoxaban for the cancer-associated asymptomatic venous thromboembolism in Japanese gastrointestinal cancer patients receiving chemotherapy (ExCAVE study) (2021) (0)
- O2-3-5Bevacizumab beyond disease progression in advanced non-squamous NSCLC (WJOG 5910L): a randomized phase II trial (2015) (0)
- 407P Long-term effect of peripheral sensory neuropathy (PSN) of 3 or 6 months oxaliplatin-based adjuvant chemotherapy for high-risk stage II colon cancer: ACHIEVE-2 as part of the IDEA collaboration (2020) (0)
- DESIGN OF CLINICAL TRIALS : NON — INFERIORITY DESIGN AND ITS APPLICATIONS — (2018) (0)
- Randomized phase II study of CDDP+S-1 vs CDDP+PEM combined with thoracic RT for locally advanced non-squamous NSCLC (2019) (0)
- A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer (2015) (0)
- Baseline creatinine clearance as an indicator of severe adverse events associated with oxaliplatin-based adjuvant chemotherapy in patients with stage III colon cancer: Safety analysis of the phase III Japanese ACHIEVE trial. (2017) (0)
- EFFECTS OF DAPAGLIFLOZIN IN HIGH AND LOW DIETARY SALT INTAKE PATIENTS WITH ALBUMINURIC DIABETIC KIDNEY DISEASE: A SUBANALYSIS OF THE Y-AIDA STUDY (2021) (0)
- Abstract B84: Can propensity score analyses be alternatives to randomized trials. (2013) (0)
- Can meta-analysis suggest carboplatin/paclitaxel as a reference arm in randomized trials of first-line chemotherapy for advanced non-small cell lung cancer? (2009) (0)
- P303 Efficacy and safety of neoadjuvant weekly paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide: A multicenter study (2011) (0)
- A phase I/II clinical trial for the hybrid of intracavitary and interstitial brachytherapy for locally advanced cervical cancer (2016) (0)
- 2152 Exploratory analysis of predictive biomarkers of oxaliplatin versus irinotecan in combination with bevacizumab for patients with metastatic colorectal cancer in WJOG4407G study (2015) (0)
- Abstract B29: Feasibility of amplicon sequencing using a pan-cancer gene panel with pre-treatment biopsy samples of (Japanese) patients with advanced solid tumors: Analyses of Biopsy Samples for Cancer Genomics (ABC) study. (2013) (0)
- Randomized phase II trial of S-1 plus cisplatin or docetaxel plus cisplatin with concurrent thoracic radiotherapy for inoperable stage III non-small cell lung cancer (TORG1018): An interim report (2016) (0)
- Relationship between basal sodium intake and the effects of dapagliflozin in albuminuric diabetic kidney disease (2021) (0)
- The best platinum regimens for chemo-naive incurable non-small cell lung cancer: network meta-analysis (2017) (0)
This paper list is powered by the following services:
Other Resources About Takeharu Yamanaka
What Schools Are Affiliated With Takeharu Yamanaka?
Takeharu Yamanaka is affiliated with the following schools:
